新型口服头孢菌素BMY-28100的体外活性

In vitro activity of BMY-28100, a new oral cephalosporin.

作者信息

Norden C W, Niederriter K

机构信息

Montefiore Hospital, Department of Medicine, University of Pittsburgh, School of Medicine, Pa.

出版信息

Chemotherapy. 1988;34(1):27-9. doi: 10.1159/000238543.

DOI:10.1159/000238543

PMID:3258231

Abstract

BMY-28100 is a new orally absorbed cephalosporin whose in vitro activity was compared with that of cefaclor. BMY-28100 was more active against Staphylococcus aureus and Haemophilus influenzae than was cefaclor. In addition, there was only a small rise in MIC50 and MIC90 values for BMY-28100 when the inoculum size was increased 100- or 10,000-fold. In contrast, MIC50 and MIC90 values increased significantly for cefaclor with similar increases in inoculum size. These data suggest that BMY-28100 may be a promising agent to test for oral administration in infections caused by S. aureus and H. influenzae.

摘要

BMY - 28100是一种新型的口服吸收性头孢菌素，其体外活性与头孢克洛进行了比较。BMY - 28100对金黄色葡萄球菌和流感嗜血杆菌的活性比头孢克洛更强。此外，当接种量增加100倍或10000倍时，BMY - 28100的MIC50和MIC90值仅略有升高。相比之下，头孢克洛的MIC50和MIC90值随着接种量的类似增加而显著升高。这些数据表明，BMY - 28100可能是一种有前景的药物，可用于测试口服治疗由金黄色葡萄球菌和流感嗜血杆菌引起的感染。